Taken together, these observations provide a rational for targeting PIM1 and PIM2 in c-MYC expressing aggressive lymphomas including ABC-DLBCL and BL, in which PIM kinase inhibition might reduce c-MYC-mediated cell proliferation. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.